Phyisician Led CIMAvax-EGF lung biomarkers
- Conditions
- Advanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases
- Registration Number
- RPCEC00000355
- Lead Sponsor
- Center of Molecular Immunology (CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 140
1. Patients of any sex and age greater than or equal to 18 years.
2. Patients who have signed the informed consent for the research.
3. Patients who meet the diagnostic criteria.
4. Patients with at least stable disease after 1st line chemotherapy, who have been included in clinical trials with the CIMAvax-EGF vaccine or have been treated as part of routine medical practice.
5. Patients who have completed the induction stage with the CIMAvax-EGF® vaccine and are receiving the vaccine as maintenance therapy.
6. Patients with clinical status criteria (ECOG) from 0 to 2
1. Patients of childbearing potential who are not using adequate contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts
2. Pregnant, lactating or postpartum patients.
3. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject.
4. Patients with brain metastases.
5. Patients with acute allergic states or history of severe allergic reactions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method